New drug combo vs standard for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial compares a new drug combination (QLS31905 plus CAPOX chemo) with another combination (sintilimab plus CAPOX) as a first treatment for advanced stomach cancer. The goal is to see which approach works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic stomach cancer or cancer of the gastroesophageal junction that has been confirmed by biopsy.
- You have not had any previous cancer treatment (like chemotherapy) for this advanced cancer.
- You are in fairly good physical condition (able to do most daily activities) and your doctor expects you to live at least 12 weeks.
- You have at least one tumor that can be measured on a scan.
- Your heart, liver, and kidneys are working well enough (you will have tests to check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two experimental drugs (QLS31905 and QL2107) plus chemotherapy (oxaliplatin and capecitabine) as the first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if the combination helps shrink tumors and control the cancer better than standard care.
This trial tests whether adding immunotherapy (sintilimab) to chemotherapy with or without lenvatinib helps people with HER2-negative stomach cancer that has spread. It compares three different treatment combinations to find the best option.
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy for people with advanced stomach cancer that hasn't been treated yet. It compares this combination to chemotherapy with or without another immunotherapy drug, nivolumab.
This trial tests a combination of an immunotherapy drug (PD1/TGFβ), another targeted drug (SHR2554 or apatinib), and chemotherapy for people who have not yet been treated for advanced stomach cancer. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
This trial tests a combination of three drugs—sintilimab (an immunotherapy), nab-paclitaxel, and tegafur/gimeracil/oteracil—as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors and control the disease.
Hear when a new Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.